Abbreviations
μg microgram
ABCC8 gene gene localization for the sulfonylurea
receptor 1
ACE angiotensin-converting enzyme
ACR albumin creatinine ratio
ADA American Diabetes Association
ADHD attention deficit/hyperactivity disorder
AER albumin excretion rate
AGA Working Group for Obesity/Arbeitsgemeinschaft
für Adipositas
AGPD Working Group for Paediatric Diabetology/
Arbeitsgemeinschaft für Pädiatrische
Diabetologie
AHCPR Agency for Health Care Policy and Research
AIHA autoimmune hemolytic anemia
Abs antibodies
ALT alanine transaminase = liver enzyme
APS Working Group for Paediatric Metabolic
Disorders/Arbeitsgemeinschaft für
Pädiatrische Stoffwechselstörungen
APS autoimmune polyglandular syndrome
AT1 blocker angiotensin II type 1 receptor blocker
AWMF German Association of the Scientific Medical
Professional Societies/Arbeitsgemeinschaft
der wissenschaftlichen medizinischen
Fachgesellschaften
BABYDIAB German BabyDiab-Study (German baby
diabetes study)
BAR Federal Working Group for Rehabilitation/
Bundesarbeitsgemeinschaft für Rehabilitation
BdKJ Association of Diabetic Children and Adolescents/
Bund diabetischer Kinder und Jugendlicher
BG blood glucose
BMI body mass index
BMI-SDS body mass index standard deviation score
BS blood sugar
CFRD cystic fibrosis-related diabetes
CGM continuous glucose monitoring
CK creatine kinase
C-peptide connecting peptide = part of proinsulin
CSII continuous subcutaneous insulin injection =
insulin pump
CT computed tomography
DAG German Obesity Society/Deutsche Adipositas
Gesellschaft
DAISY Diabetes Autoimmunity Study of the Young
(autoimmunity study for adolescents with
diabetes)
DCC-Trial Diabetes Control and Complications Trial
(study on the control and complications of
diabetes)
DDG German Diabetes Society/Deutsche
Diabetes Gesellschaft
DENIS German Nicotinamide Intervention Study/
Deutsche Nicotinamide-Intervention-Study
DEPS-R Diabetes Eating Problem Survey – Revised
DGE German Nutrition Society/Deutsche
Gesellschaft für Ernährung
DGEM German Society for Nutritional Medicine/
Deutsche Gesellschaft für Ernährungsmedizin
DGKJP German Society for Paediatric and Adolescent
Psychiatry, Psychosomatics and Psychotherapy/
Deutsche Gesellschaft für Kinderund
Jugendpsychiatrie, Psychosomatik und
Psychotherapie
diab. diabetic
diabetesDE Diabetes Germany
DIAMYD Diamyd® Study
DIPP Diabetes Prediction and Prevention Project
DKA diabetic ketoacidosis
dl decilitre
DNSG Diabetes And Nutrition Study Group
DPT-1 Diabetes Prevention Trial – Type 1
DPM Diabetes patient management (documentation
system)
EASD European Association for the Study of
Diabetes
EDIC-Trial Epidemiology of Diabetes Interventions and
Complications Trial = Follow-up Study of
the DCC Trial
EIF2AK3 gene locus for mutations leading to a
genetic syndrome with diabetes
EC evidence class (methodological quality of a
study according to criteria of evidencebased
medicine)
ECG electrocardiogram
EMA European Medicines Agency
European Nicotinamide Intervention Trial
ES educational support (therapeutic support in
parenting)
ethn. ethnic
fam. familiar
FES family environment scale = scale for the
evaluation of social characteristics and the
environment of families
FOXP3 gene locus for mutations leading to genetic
syndromes with diabetes
FST-D family system therapy for patients with
diabetes
fT3 free triiodothyronine
fT4 free thyroxine
g gram
GAD glutamate decarboxylase
GCK glucokinase
h hour
HbA1c glycated haemoglobin
HDL high-density lipoprotein
HHS hyperosmolar hyperglycaemic syndrome
HLA human leukocyte antigen
HNF hepatocyte nuclear factor
HTA health technology assessment = systematic
assessment of medical technologies,
procedures aids and organizational
structures, in which medical services are
provided
I.U. international unit(s)
i. m. intramuscular
IV intravenously
IA-2 tyrosine phosphatase IA-2 antibody
IAA insulin autoantibody
ICA islet cell antibody
ICT intensified conventional insulin therapy
IgA immunoglobulin A
IgG immunoglobulin G
INS insulin(s)
IPEX immunodysregulation polyendocrinopathy
enteropathy X-linked syndrome
IPF-1 insulin promoter factor 1 = gene locus with
mutations leading to MODY-4 diabetes
IRMA intraretinal microvascular anomaly
ISPADISPAD International Society for Paediatric and
Adolescent Diabetes
ITP immune thrombocytopenic purpura
Y years
n/a not available
kcal kilocalories
KCNJ11 inward-rectifier potassium ion channel,
subfamily J, member 11
kg kilogram
BW body weight
Kir6.2 gene locus for KCNJ11
KJHG child and youth welfare law
l litre
LDL low-density lipoprotein
LGS low-glucose suspend
m2 square meters
max. maximum
mg milligram
micro microalbuminuria
min. minimum
avg. average
MJ megajoule
ml millilitre
mm millimetre
mmHg millimetres of mercury = used to measure
blood pressure
mmol millimole
mon month(s)
MODY maturity onset diabetes of the young (adult
diabetes in adolescents) = monogenetic
diabetes
MRI magnetic resonance imaging
n number
NaCl sodium chloride
NDM neonatal diabetes mellitus
NCV nerve conduction velocity
NPH insulin neutral protamine Hagedorn insulin
NYHA New York Heart Association classification
system for the severity of heart failure
OGTT oral glucose tolerance test
p p-value/probability value – exceeding
probability, statistical information
PAL value physical activity level (value for measuring
the daily physical activity expenditure)
Pat. patient(s)
pCO2 arterial partial pressure of carbon dioxide
pH potentia hydrogenii (capacity of hydrogen)
= negative logarithm of the hydrogen
ion concentration/activity, measure for
acidity of a medium
PLGM predictive low glucose management
PNDM permanent neonatal diabetes mellitus
RCT randomized controlled trial
RR Riva Rocci = arterial blood pressure, measured
according to the method of Riva Rocci
s. c. subcutaneous
SC standard care (standard treatment)
SEARCH search for diabetes in the youth study
(studies for the identification of diabetes in
children and adolescents)
SGB German Social Code Book/Sozialgesetzbuch
SIGN Scottish Intercollegiate Guidelines Network
sign. significant
SSRI selective serotonin reuptake inhibitor
STIKO Standing Vaccination Commission of the
Federal Republic of Germany/Ständige
Impfkommission der Bundesrepublik
Deutschland
SaP sensor-augmented pump therapy
SUR 1 sulphonylurea receptor 1
SaT sensor-augmented insulin therapy
T3 triiodothyronine
T4 thyroxine
daily daily
tTG-IgA tissue transglutaminase antibodies
Tg thyroglobulin
TNDM transient neonatal diabetes mellitus
TPO thyroid peroxidase
TSHR thyrotropin receptor
TRIGR Trial to Reduce IDDM in the Genetically at the
Risk (Study on the reduction of diabetes mellitus
by immunodeficiency for genetical risks)
TSH thyroid-stimulating hormone/thyrotropin
U unit
UK United Kingdom
esp. especially
vs. versus
WHO World Health Organization
c. a. condition after
CNS central nervous system
ZnT8 zinc transporter 8
The DDG clinical practice guidelines are updated regularly
during the second half of the calendar year. Please ensure
that you read and cite the respective current version.
Causes and background
The improvement of the care of children and adolescents with diabetes mellitus is
an
essential task of the Working Group for Paediatric Diabetology/Arbeitsgemeinschaft
für Pädiatrische Diabetologie (AGPD).
In order to meet the needs of a chronic disease in childhood and adolescence,
specific aspects of this stage of life must be taken into account.
These guidelines are addressed to all professional groups that care for and support
children and adolescents with diabetes and their families, as well as to
higher-level organisations (e. g. health insurance companies) that are involved with
or affected by the disease.
In accordance with the specifications of the health ministers of the federal German
states as well as the current practice of many clinics, these paediatric guidelines
are valid until the age of up to 18 years. In individual clinical cases, however,
these guidelines can also be extended to apply to early adulthood.
Epidemiology and types of diabetes in childhood and adolescence
Epidemiology and types of diabetes in childhood and adolescence
Type 1 diabetes
Type 1 diabetes is still the most common metabolic disease in children. According
to current estimates, 15600 to 17400 children and adolescents aged 0–14 years
live with type 1 diabetes in Germany [Rosenbauer et al. 2013]. At the beginning
of the millennium, 21000 to 24000 children and adolescents aged 0–19 years were
affected [Rosenbauer et al. 2002]. This figure is currently estimated at around
30000 to 32000 [Rosenbauer et al. 2012].
In the 1990s, average annual new illness rates (incidence rates) were reported
between 12.9 (95% confidence interval 12.4–13.4) and 14.2 (95% confidence
interval 12.9–15.5) per 100000 children aged 0–14 years and 17.0 (95% confidence
interval 15.2–18.8) per 100000 children aged 0–19 years [Neu et al. 2001;
Rosenbauer et al. 2002; Neu et al. 2008]. The incidence rate has increased by
3–4% per year [Ehehalt et al. 2008; Neu et al. 2013]. Compared to the early
1990s, the new illness rate for 0–14-year-olds has now doubled and is currently
22.9 (95% confidence interval 22.2–23.6). The increase in incidence rates
especially affects the younger age groups.
Type 2 diabetes
Parallel to the increase in the prevalence of excess weight and obesity in
childhood and adolescence [Kurth and Schaffrath 2007; Kromeyer-Hauschild et al.
2001], the incidence of type 2 diabetes has increased in this age group. Initial
population-based estimates of type 2 in children and adolescents showed an
incidence of 1.57 per 100000 in 2002 (95% confidence interval 0.98–2.42)
[Rosenbauer et al. 2003]. Studies carried out in Baden-Württemberg in 2004
showed that type 2 diabetes in Germany occurs in 0 to 20-year-olds with a
prevalence of 2.3 per 100000 [Neu et al. 2005]. A second cross-sectional survey
in Baden-Württemberg conducted in 2016 confirmed the relatively low and constant
incidence of 2.4 per 100000 [Neu et al. 2017].
Risk factors, prevention and early detection of diabetes
Risk factors, prevention and early detection of diabetes
According to the current guidelines of the International Pediatric Diabetes
Association/Internationalen Pädiatrischen Diabetesgesellschaft ISPAD, the
progression of type 1 diabetes has recently been divided into 4 stages [Couper
2018]. Stage 1, the beginning of type 1 diabetes according to the new
classification, is when 2 or more diabetes-specific autoantibodies are detectable
but children and adolescents are completely asymptomatic. If glucose tolerance is
impaired, this corresponds to stage 2. Stage 1 and stage 2 can precede months and
years of clinical manifestation. Stage 3 is when there is a manifestation and stage
4 is the case of a type 1 diabetic who has lived with the disease for some time.
Measures to maintain beta cell function can start before the onset of islet
autoimmunity (early stage 1, primary prevention), after the development of
autoantibodies but before clinical symptoms (stages 1 and 2) or rapidly after the
manifestation of type 1 diabetes (stage 3). The progression of type 1 diabetes with
proven autoantibodies occurs more rapidly with seroconversion to islet autoimmunity
before the 3rd year of life and in children with an HLA-DR3/DR4-DQ8
genotype [Ziegler 2013]. The 5 and 10-year risk of type 1 diabetes manifestation in
children who show multiple autoantibodies at the age of 5 years or earlier is 51 and
75%, respectively [Danne et al., 2018], German Health Report Diabetes/Dt.
Gesundheitsbericht Diabetes].
Type 1 diabetes
The diagnosis of type 1 diabetes is based on clinical symptoms and blood glucose
monitoring. In case of doubt, further parameters can be used for diagnosis.
These include:
-
Autoantibodies associated with diabetes (cytoplasmic islet cell
antibodies [ICA], insulin autoantibodies [IAA], antibodies against
glutamate decarboxylase [anti-GAD65], antibodies against tyrosine kinase
IA-2 [anti-IA-2A], antibodies against zinc transporter-8 [anti
ZnT8]),
-
An oral glucose tolerance test and
-
HbA1c determination [Ehehalt et al. 2010; Mayer-Davis EJ. 2018].
10–15% of all children and adolescents under the age of 15 with type 1 diabetes
have first-degree relatives with diabetes and thus a positive family history
[Rosenbauer et al. 2003; Scottish Study Group for the Care of the Young Diabetic
2001]. The risk of developing diabetes is 3 times higher for children with a
father suffering from diabetes than for children with a mother suffering from
diabetes [Gale et al. 2001]. While antibodies and other markers might provide a
prediction and risk calculation regarding the occurrence of diabetes, there are
no effective prevention strategies that could prevent the manifestation of
diabetes [Rosenbloom et al. 2000; Australasian Paediatric Endocrine Group et al.
2005].
A general screening for type 1 diabetes should therefore not be performed in the
general population or in high-risk groups among children and adolescents
[Australasian Paediatric Endocrine Group et al. 2005]. According to the latest
recommendations gleaned from scientific studies, screening and intervention in
the absence of symptoms of type 1 diabetes remain reserved [Couper 2018].
Type 2 diabetes
An oral glucose tolerance test for the early detection of type 2 diabetes should
be performed as of age 10 in cases of excess weight (BMI>90th percentile) and
the presence of at least 2 of the following risk factors:
-
Type 2 diabetes in 1st or 2nd degree relatives,
-
Belonging to a group with increased risk (e. g. East Asians, African
Americans, Hispanics),
-
Extreme obesity (BMI>99.5th percentile) or
-
Signs of insulin resistance or changes associated with it (arterial
hypertension, dyslipidaemia, elevated transaminases, polycystic ovarian
syndrome, acanthosis nigricans)
[Working Group for Obesity in Childhood and Adolescence/Arbeitsgemeinschaft
Adipositas im Kindes- und Jugendalter AGA 2008].
Therapy for type 1 diabetes
Therapy for type 1 diabetes
Start of therapy
Insulin therapy should be initiated immediately after the diagnosis of type 1
diabetes, as the child’s metabolism can deteriorate rapidly. A diabetes team
experienced with children should be called in as soon as possible [Bangstad et
al. 2007].
Therapy goals
Initial treatment and long-term care should be carried out by a team experienced
in paediatric diabetology continuously from ages 1–18, and, in certain cases,
also up to the age of 21. Specialised care has been shown to contribute to a
reduction in days spent in hospital and readmissions, to a lower HbA1c value,
better disease management and fewer complications [Cadario et al. 2009; Pihoker
et al. 2014; Australasian Paediatric Endocrine Group et al. 2005].
The treatment of type 1 diabetes by the treatment team should include:
-
Insulin therapy,
-
Individual metabolic self-monitoring,
-
Age-adapted structured training as well as
-
Psychosocial care for the affected families.
The following medical goals are in the foreground when caring for paediatric
patients with diabetes mellitus [Danne et al. 2014; Ziegler 2018]: avoidance of
acute metabolic lapses, prevention of diabetes-related microvascular and
macrovascular secondary diseases and normal physical development (growth in
height, weight gain, onset of puberty). The patient’s psychosocial development
should be affected as little as possible by diabetes and its therapy, and
integration and inclusion in day care, school and vocational training should be
ensured.
Individual therapy goals should be formulated together with the child or
adolescent and his or her family (HbA1c value, blood glucose target ranges,
behavioural changes that come with risk-taking lifestyles, integration efforts,
etc.).
The HbA1c target value of<7.5% was modified in 2018 by the ISPAD to a new
target value of<7.0%, the American Diabetes Association (ADA) recommendations
still lie at<7.5%, whereas the English National Institute for Health and Care
Excellence (NICE) recommendations assume a target value of<6.5% [DiMeglio et
al., 2018].
An additional parameter for evaluating the metabolic state is the time spent in
the target range (TiR = time in range). Generally, the target range is defined
as 70–180 mg/dl. An individual goal for the duration of the TiR is recommended
[Danne 2017; Battelino T. 2019].
Preprandial glucose values should be between 70 and 130 mg/dl (4.0–7.0 mmol/l)
and postprandial values between 90 and 180 mg/dl (5.0–10.0 mmol/l). Values of
80–140 mg/dl (4.4–7.8 mmol/l) are recommended at bedtime [DiMeglio 2018].
The average frequency of glucose control should be between 5 and 6 times a day
but can be significantly higher in individual cases [Ziegler et al. 2011].
Continuous treatment of type 1 diabetes
The continuity of the treatment of diabetes mellitus of a child or adolescent
with diabetes, both over time and during different phases of life and
development, is decisive for ensuring a metabolic situation as close as possible
to normoglycaemia and an unencumbered psychosocial development.
Care of children in day cares and schools
Children with diabetes should be cared for in day cares, regular schools and
after-school centres [Hellems and Clarke 2007]. The right to inclusion is
laid down in § 53 and § 54 of the German Social Code Book
XII/Sozialgesetzbuch XII. This provides the basis for the assumption of
costs for age-appropriate care.
An individual plan should be created for each institution which includes the
frequency and intervention limits of blood glucose measurements, the
delivery of insulin (mode, time, dose calculation), defining of mealtimes,
symptoms and management of hypoglycaemias and hyperglycaemias [American
Diabetes Association (ADA) 2015]. In addition to children, adolescents and
their parents, all caregivers in the social environment must also be trained
to enable inclusion [Ziegler 2018].
Support during the transition to young adulthood
The transition from paediatric to adult care affects young people with
diabetes aged 16–21 years in a life phase of general upheaval and should
therefore be accompanied. Various models (transitional consultations,
structured paediatric/internal medicine transition, etc.) are in use [Nakhla
et al. 2008; Australian Paediatric Endocrine Group et al. 2005; Court JM et
al., 2008].
Care in case of illness and preventing illness risks
In the case of serious illnesses or in perioperative cases, children with
diabetes should be referred to an experienced centre with well-trained
staff, and the paediatric diabetologist should also be consulted [Brink et
al. 2007].
Under no circumstances should insulin be completely omitted in the case of
low glucose levels or refusal to eat. The administration of carbohydrates is
necessary in order to avoid substrate deficiency and ketone body formation.
The possibility of measuring β-hydroxybutyrate should be provided [Laffel
2018].
Children with diabetes mellitus should be vaccinated according to STIKO
(Ständige Impfkommission/Standing Committee on Vaccination)
recommendations.
Diabetes treatment during physical activity/sports
Regular exercise improves metabolic control and should be a matter of course
for children and adolescents with diabetes. Regular swimming has been shown
to significantly reduce HbA1c [Sideravicite et al. 2006].
Since blood glucose is lowered by energy consumption during physical
activity, the risk of hypoglycaemia is increased. The strongest predictor
for hypoglycaemia is the initial glucose value, which should be at least 120
mg/dl (6.6 mmol/l); otherwise additional carbohydrates may be required
[Tansey et al. 2006]. Individual therapy plans with insulin dose adjustment
and corresponding behavioural rules should be put together for each patient
[Adolfsson 2018].
Insulin treatment
The standard treatment for paediatric patients with type 1 diabetes is
intensified insulin therapy [Danne 2018].
All insulin therapy should be carried out as part of comprehensive diabetic care
and with the support of the family.
Insulin therapy should be individually tailored to each child [Diabetes Control
and Complications Trial Research Group 1995; White et al. 2008; Nathan et al.
2005; Musen et al. 2008].
Human insulin or insulin analogues should be used for paediatric patients
[Bangstad et al. 2007; Danne et al. 2005; Mortensen et al. 2000; Deeb et al.
2001; Plank et al. 2005; Simpson et al. 2007].
Normal insulin should be used for intravenous insulin treatment.
Rapid-acting insulin and insulin analogues (prandial
substitution)
There are differences between rapid-acting human insulin and fast-acting
insulin analogues in the onset and duration of action in children and can be
used flexibly for prandial substitution in children depending on the
situation [Danne et al. 2005; Mortensen et al. 2000].
Rapid-acting insulin analogues should be used for insulin pump therapy.
Long-acting insulin and insulin analogues (basal substitution)
Both NPH insulin and long-acting insulin analogues can be used individually
for basal insulin substitution in children [Danne et al. 2003; Danne et al.
2008; Thisted et al. 2006; Robertson et al. 2007; Danne et al. 2013;
Thalange et al. 2015].
Insulin pump therapy
Insulin pump therapy for children and adolescents is both safe and effective.
It has a positive effect on the frequency of hypoglycaemia, ketoacidosis and
the metabolism [Karges et al., 2017]. Particularly in young children, pump
therapy enables better adjustment of the insulin dose, especially at night,
thus helping to prevent hypoglycaemias. Insulin pump therapy is recommended
for the following indications:
-
Small children, especially newborns, infants and preschoolers,
-
Children and adolescents with a marked increase in blood glucose in
the early morning hours (Dawn phenomenon),
-
Severe hypoglycaemias, recurrent and nocturnal hypoglycaemias
(despite intensified conventional therapy = ICT),
-
HbA1c value outside target range (despite ICT),
-
Severe blood glucose fluctuations, despite ICT, independent of the
HbA1c value,
-
Incipient microvascular or macrovascular secondary diseases,
-
Limitation of the quality of life through previous insulin
therapy
-
Children with a great fear of needles,
-
Pregnant adolescents (ideally before conception in the case of a
planned pregnancy) as well as
-
Competitive athletes [Phillip et al. 2007].
Continuous glucose monitoring (CGM), sensor-augmented insulin therapy
(SaT) and sensor-augmented pump therapy (SaP)
CGM systems have been approved and can be prescribed for children and
adolescents. They are available in the form of rt (real-time) CGM systems
and in the form of isc (intermittent scanning) CGM systems. They can be used
in combination with ICT (sensor-augmented insulin therapy = SaT). Some CGM
systems can be used together with an insulin pump, or the insulin pump can
serve as a monitor for CGM data. This combination (CSII + CGM) is now called
sensor-augmented pump therapy (SaP). In addition, there is the possibility
of switching off the basal rate when the tissue glucose reaches a critical
limit (SaP + LGS = low-glucose suspend). A further development of the LGS
already interrupts the supply of insulin if it predicts that hypoglycaemia
will occur in the foreseeable future (predictive insulin switch-off,
predictive low-glucose suspend = PLGS). The combination of both systems is
called sensor-integrated pump therapy (SiP). Recently, CGM and insulin pumps
have been combined to form an “AID system” (automated insulin delivery). An
algorithm continuously calculates the respective insulin dose from the
measured tissue glucose values, taking into account individual user data.
Currently, “hybrid AIDs” are available for children and adolescents with
type 1 diabetes. Here, the term “hybrid” means that the supply of the
food-independent, basal insulin component takes place automatically
according to the current insulin requirement and the insulin continues to be
delivered manually by the user at mealtimes. All studies have shown that
such hybrid AID systems can improve metabolic control in children,
adolescents and adults with type 1 diabetes at night, but also during the
day.
Soon, “Advanced AID Systems” will be available, which, in addition to
adjusting the basal rate at higher glucose values, will automatically
deliver small insulin microboli as an additional correction.
CGM should be used for children and adolescents with type 1 diabetes
-
To reduce the hypoglycaemia rate (frequency, duration, depth) or
-
In cases of recurrent nocturnal hypoglycaemia or
-
In cases of a lack of hypoglycaemia perception or
-
In cases of severe hypoglycaemia or
-
To improve metabolic control without a simultaneous increase in
hypoglycaemias or
-
To reduce pronounced glucose variability
[Bergenstal et al. 2013; Ly et al. 2013; Maahs et al. 2014].
CGM should be used in paediatric patients with type 1 diabetes who have not
achieved their HbA1c targets after having considered and used other measures
and training courses for optimizing metabolic control [Battelino et al.
2012; Bergenstal et al. 2010; Danne 2017; Sherr 2018].
Nutritional recommendations
Nutritional counselling for children and adolescents with diabetes is an
important part of a comprehensive therapy training plan and should include the
following components:
-
Information on the blood glucose efficacy of carbohydrates, fats and
proteins,
-
Strengthening healthy diets as part of family meals and in public
institutions: regular, balanced meals and snacks (fruit, vegetables, raw
vegetables), prevention of eating disorders (especially uncontrolled,
binge eating) and the prevention of excess weight,
-
Consideration of cultural eating habits,
-
Enough energy for age-appropriate growth and development,
-
Working toward a normal BMI, which includes regular physical
activity,
-
A good balance between energy intake and consumption in accordance with
the insulin profiles,
-
Nutrition during illness and sport and
-
Reducing the risk of cardiovascular disease.
Nutrition specialists (dieticians/ecotrophologists) with an in-depth knowledge of
paediatric and adolescent nutrition and insulin therapy should provide this
counselling [Smart et al. 2014; Craig et al. 2011].
Nutritional recommendations should include all dietary components and their share
in daily energy intake [German Nutrition Society/Deutsche Gesellschaft für
Ernährung (DGE) 2015].
Diabetes training
Patient training is an essential part of diabetes therapy. It cannot be
successful without proper, individualised medical treatment [Bloomgarden et al.
1987; de Weerdt et al. 1991].
Children, adolescents and their parents or other primary caregivers should have
continuous access to qualified training starting from the time of diagnosis
onwards [Craig et al. 2011; Bundesärztekammer (BÄK) et al. 2012; Canadian
Diabetes Association Clinical Practice Guidelines Expert Committee 2013; Kulzer
et al., 2013; Martin et al. 2012; Lange et al. 2014; Haas et al. 2014].
Training should be offered to caregivers in institutions (e. g. teachers in
schools, educators in day cares, nurseries, after-school centres or group homes)
[Hellems et al. 2007; Lange et al. 2012; Clarke et al. 2013].
The training should be conducted by a multi-professional diabetes team with
proper knowledge of age-specific needs, possibilities and requirements that
current diabetes therapies place on patients and their families.
All team members should participate in the training and work toward formulating
and achieving uniform therapy concepts and goals [Swift et al. 2010; Lange et
al. 2014; Cameron et al. 2013].
The learning process should be accompanied by evaluated training materials that
are oriented towards the cognitive development and needs of children and
adolescents. The same applies to training materials for parents which should
include parenting tasks and age-specific diabetes therapy of their children
[Martin et al. 2012; Lange et al. 2012; Lange et al. 2014].
Diabetic training is a continuous process and can only be successful through
repeated needs-based offers (at least every 2 years) during long-term care. New
therapy concepts, e. g. the start of insulin pump therapy or continuous glucose
monitoring (CGM) and new life stages (e. g. starting school) should be
accompanied by additional training. Other diseases (e. g. celiac disease or
attention deficit/hyperactivity disorder ADHD) or acute complications (e. g.
DKA, severe hypoglycaemias) or psychological problems require personalised
treatment [Jacobson et al. 1997; Haas et al. 2014; Lange et al. 2014; Delamater
et al. 2014].
Rehabilitation
In-patient rehabilitation can be carried out:
-
In the case of persistently poor skills in dealing with diabetes,
-
If there are diabetic secondary complications which are either already
present or imminent in the short-term,
-
After the in-patient primary therapy of the newly diagnosed diabetes
mellitus if initial training cannot be provided near the patient’s home
(in the form of follow-up treatment),
-
In the case of long-term inadequate metabolic control under out-patient
care conditions, e. g. recurrent hypoglycaemia or ketoacidosis, and
-
In the event of serious disruptions to activities and/or to the child or
adolescent being able to participate in age-appropriate activities or in
everyday life, e. g. frequent sick days (§ 4 SGB 9; Federal Working
Group for Rehabilitation/Bundesarbeitsgemeinschaft Rehabilitation)
[Federal Working Group for Rehabilitation/Bundesarbeitsgemeinschaft für
Rehabilitation (BAR) 2008; Fröhlich et al. 2008; German Pension Insurance
Association/Deutsche Rentenversicherung Bund 2009; German Society for Paediatric
Rehabilitation and Prevention/Deutsche Gesellschaft für pädiatrische
Rehabilitation und Prävention 2007; Stachow et al. 2001].
Psychological and social risks, comorbidities and interventions
Psychological and social risks, comorbidities and interventions
In the case of a diabetes diagnosis, a history of the psychosocial family situation
should be recorded. The families should also receive psychosocial counselling and
the interdisciplinary team should provide them with therapeutic aids for diabetes
management. The psychological situation of the parents and other primary caregivers
also needs be taken into account [Hürter et al. 1991; Sundelin et al. 1996;
Delamater et al. 1990; Craig et al. 2011; Delamater et al. 2014; Forsander et al.
1998; Sullivan-Bolyai et al. 2011; Forsander et al. 2000; Zenlea et al. 2014].
The current psychosocial situation and possible stressful life events should be
continuously recorded within the framework of long-term care (intellectual,
academic, emotional and social development) and taken into account in therapy
planning.
For this reason, it is important for social workers and psychologists with
diabetes-specific expertise to be an integral part of the interdisciplinary diabetes
team [Silverstein et al. 2005; Craig et al. 2011; de Wit et al. 2008; Delamater et
al. 2014; Kulzer et al. 2013; Hilliard et al. 2011; Haas et al. 2014; de Wit et al.,
2012].
Particularly in adolescents, signs of eating disorders and mood affective disorders
(e. g. anxiety, depression, adjustment disorders) should be monitored and
professional help sought and carried out in a timely manner.
If a psychiatrically-relevant disorder is present, paediatric and adolescent
psychiatrists or psychological psychotherapists should be consulted in order to
initiate co-treatment if necessary. A coordinated treatment between psychiatrist and
diabetes team should be strived for [Northam et al. 2005; Lawrence et al. 2006;
Delamater et al. 2014; Kulzer et al. 2013; Young et al. 2013].
Children and adolescents with diabetes have an increased risk of impaired information
processing and learning. Children with early onset diabetes, severe hypoglycaemias
and chronic hyperglycaemias in early life are particularly affected.
Therefore, the school performance of children with increased risk (diabetes diagnosis
under 5 years, severe hypoglycaemias/chronic hyperglycaemias) should be recorded.
In
case of learning difficulties, they, just as all children, should be assessed
neuro-physiologically and psychologically and, if necessary, receive educational
support [Delamater et al. 2014].
Acute complications
Diabetic ketoacidosis
Diabetic ketoacidosis is a potentially life-threatening disease. It should be
treated immediately in a specialized facility by a diabetes team experienced
with children. There should be a written treatment plan for treating diabetic
ketoacidosis in children and adolescents [Australasian Paediatric Endocrine
Group et al. 2005; Glaser et al. 2006; Fiordalisi et al. 2007].
The biochemical criteria for ketoacidosis include:
-
pH<7.3,
-
Bicarbonate<15 mmol/l,
-
Hyperglycaemia>11 mmol/l,>200 mg/dl and
-
Ketonuria and presences of ketones in serum.
Ketoacidosis is categorised into 3 stages of severity:
-
Mild (pH<7.3; bicarbonate<15 mmol/l),
-
Moderate (pH<7.2; bicarbonate<10 mmol/l) and
-
Severe (pH<7.1; bicarbonate 5 mmol/l)
[Wolfsdorf et al. 2007].
The following therapy goals are to be pursued in ketoacidosis:
-
Stabilisation of the cardiovascular system with initial volume bolus
using isotonic solution,
-
Subsequent slow, balanced fluid resuscitation and electrolyte
replacement,
-
Slow normalization of blood glucose,
-
Balancing out of acidosis and ketosis,
-
Avoidance of therapy complications (cerebral oedema, hypokalaemia,
hypophosphatemia) and
-
Diagnosis and therapy of triggering factors
-
[Australasian Paediatric Endocrine Group et al. 2005b; Wolfsdorf et al.
2018] ([Table 1]).
Table 1 Medicinal treatment of ketoacidosis (taking the
control of electrolytes, pH, blood glucose, ketone bodies into
consideration).
|
Treatment goal/indication
|
Medicine
|
Dose
|
Chronological sequence
|
|
Initial stabilisation of cardiovascular system, if
necessary
|
NaCl 0.9%
|
10–20 ml/kg IV
|
Immediately over 1–2 h
|
|
Fluid resuscitation after initial cardiovascular
stabilisation
|
NaCl 0.9% or Ringer’s solution, after 4–6 h NaCl 0.45% also
possible
|
Maximum daily IV dose<1.5 to 2 times the maintenance
requirement in relation to age/weight/body
|
At least over 36–48 h
|
|
Lowering of blood glucose
|
Normal insulin
|
0.1 U/kg/h IV, for younger children 0.05 U/kg/h
|
Begin insulin administration 1–2 h after start of volume
administration; no interruption of insulin delivery up to
pH>7.3; lowering of blood glucose by 2–5 mmol/l/h (36–90
mg/dl/h)
|
|
Avoidance of hypoglycaemia
|
Glucose
|
Final concentration: 5% glucose/0.45% NaCl solution
|
Start from BG as of 15 mmol/l (270 mg/dl) or at lowering of
BG>5 mmol/l/h (90 mg/dl/h)
|
|
Balance of potassium
|
KCl
|
40 mmol/l volume; 5 mmol/kg/day IV; not>0.5 mmol/kg/h
|
For hypokalaemia immediately, for normokalaemia together with
the start of insulin administration, in the case of
hyperkalaemia only after resumption of urine production;
continuous administration until volume compensation has been
fully compensated
|
|
Balance of phosphates
|
Potassium phosphate
|
At pH<7.1 half the potassium substitution as potassium
phosphate
|
Until phosphate is in the normal range again
|
NaCl: Sodium chloride; BG: Blood glucose; KCl: Potassium chloride, IV:
intravenously, U: unit, h: hour.
During the treatment of severe diabetic ketoazidoses, clinical observation and
monitoring should take place at least every hour [Australasian Paediatric
Endocrine Group 2005; Edge et al. 2006; Wolfsdorf et al. 2018].
Patients with severe ketoacidosis and an increased risk of cerebral oedema should
be treated immediately in an intensive care unit or a specialized diabetes unit
with comparable equipment by a diabetes team experienced with children.
Patients with suspected cerebral oedema should be treated in an intensive care
unit in cooperation with an experienced diabetes team [Australasian Paediatric
Endocrine Group et al. 2005; Wolfsdorf et al. 2018].
Patients with clear signs of cerebral oedema should be treated with mannitol or
hypertonic saline solution before further diagnostic measures (MRI) are
initiated [Australasian Paediatric Endocrine Group et al. 2005; Fiordalisi et
al. 2007; Hanas et al. 2007; Roberts et al. 2001; Franklin et al. 1982; Banks et
al. 2008; Wolfsdorf et al. 2018].
Case reports or case series are available on the therapeutic efficacy in
symptomatic cerebral oedema of an early intravenous mannitol administration
(0.5–1 g/kg) over 10–15 min and repeated if necessary (after 30 min.)
[Fiordalisi et al. 2007; Hanas et al. 2007; Roberts et al. 2001; Franklin et al.
1982].
Hypoglycaemia
Hypoglycaemia is the most common acute complication in diabetes [Diabetes Control
and Complications Trial Research Group 1994].
According to the latest recommendation by the Hypoglycaemia Study Group
[International Hypoglycaemia Study Group 2017], a distinction is made between
blood glucose values into the following:
Stage 1:<70 mg/dl (3.9 mmol/l), requires attention and treatment, if
necessary
Stage 2:<54 mg/dl (3 mmol/l), always requires immediate treatment and
Stage 3: with impaired consciousness, always requires immediate treatment.
Slight hypoglycaemia can be corrected by the patient through the intake of
fast-acting carbohydrates.
Severe hypoglycaemia can only be remedied with external help due to the
accompanying limitation or loss of consciousness. In addition to a loss of
consciousness, a severe hypoglycaemia can also be accompanied by a cerebral
seizure.
Children and adolescents with type 1 diabetes should always carry fast-acting
carbohydrates in the form of dextrose or the like, in order to be able to act
immediately in the event of mild hypoglycaemia and thus prevent severe
hypoglycaemia. Parents or other primary caregivers should be instructed in the
use of glucagon injections or other immediate measures.
Caregivers in e. g. day cares and day care centres, and teachers in schools
should also receive instruction on the risks and treatment options for
hypoglycaemia.
In the case of hypoglycaemia perception disorder, a higher blood glucose level
should be temporarily set [Australasian Paediatric Endocrine Group et al. 2005;
Clarke et al. 2008]. The use of a CGM system with hypoglycaemia suspend should
also be considered.
Long-term complications and preventive examinations (screening)
Long-term complications and preventive examinations (screening)
The HbA1c value should be determined at least every 3 months to check metabolic
control [Diabetes Control and Complications Trial Research Group 1994; Nathan et al.
2005; White et al. 2008]. All other long-term controls are listed in [Table 2].
Table 2 Long-term complications: screening examinations and
interventions.
|
Screening examination and intervals
|
Recommended screening method(s)
|
Interventions
|
|
1. Retinopathy:
|
|
|
Binocular bi-microscopic funduscopy in mydriasis by experienced
ophthalmologist
|
|
|
2. Nephropathy:
|
|
|
Detection of microalbuminuria:
-
Concentration measurement: 20–200 mg/l
-
Albumin excretion rate>20 to<200 μg/min
-
Albumin-creatinine ratio
-
24-hour urine collection, if necessary
|
-
Improvement of glycaemic control
-
For hypertension + microalbuminuria:
-
ACE inhibitors
-
AT-1 blockers
-
Persistent microalbuminuria without hypertension:
consider ACE inhibitors
-
Nicotine abstinence
|
|
3. Nephropathy:
|
|
|
|
|
|
4. Hypertension:
|
|
|
|
-
Lifestyle intervention (exercise, salt reduction, weight
reduction, reduction of alcohol and/or nicotine)
-
If not successful: ACE inhibitors; for contraindications
or side effects: AT-1 blockers; combination with other
drugs if required
|
|
5. Hyperlipidaemia:
|
|
|
Detection of
-
Total cholesterol
-
HDL cholesterol
-
LDL cholesterol
-
Triglycerides
|
|
ACE: angiotensin converting enzyme; AT: angiotensin; HDL: High-density
lipoprotein; LDL: Low-density lipoprotein.
Associated autoimmune diseases
Associated autoimmune diseases
Diagnostics and therapy of thyroid diseases
In children and adolescents with diabetes, determination of the
thyroid-stimulating hormone (TSH) and determination of thyroid autoantibodies
(antibodies against thyroid peroxidase [TPOAb] and thyroglobulin [TgAb]) should
be performed upon diabetes manifestation and at regular intervals of 1–2 years
or with associated symptoms [Australasian Paediatric Endocrine Group et al.
2005; Bangstad et al. 2007; Silverstein et al. 2005; Kordonouri et al.
2011].
If TPO autoantibodies and/or a TSH increase are present, a sonography of the
thyroid should be performed.
For the therapy of autoimmune hypothyroidism or struma, L-thyroxine should be
used according to the therapy plan ([Fig.
1])
Fig. 1 Diagram for treating Hashimoto’s thyroiditis. Source: Diagnosis, Therapy and Follow-Up
of Diabetes Mellitus in Children and Adolescents.
S3-Guideline of the DDG and AGPD 2015. German Association of the Scientific Medical
Professional Societies/AWMF registration number 057–016
[rerif]. TSH: thyroid-stimulating hormone; fT4: free thyroxine.
Diagnostics and therapy of celiac disease
Children and adolescents with diabetes are to be examined for celiac disease in
the event of diabetes manifestation and at intervals of 1–2 years and in the
case of associated symptoms [Australasian Paediatric Endocrine Group et al.
2005; Hill et al. 2005; Silverstein et al. 2005; Kordonouri et al. 2007;
Kordonouri et al. 2014; Kordonouri et al. 2011].
In cases of confirmed celiac disease (serologic and bioptic) with symptoms or
extraintestinal manifestation, a gluten-free diet should be followed [Hansen et
al. 2006; Amin et al. 2002; Hill et al. 2005; Lewis et al. 1996; Kordonouri et
al. 2011].
According to the latest recommendations, a biopsy can be dispensed with in the
case of clear clinical symptoms, high anti-tissue transglutaminase (anti-TG2)
immunoglobulin A (IgA) autoantibodies (>10 times above norm) and endomysium
antibodies as well as a positive HLA-DQ2 or DQ8 haplotype [Mahmud 2018].
However, this recommendation is inconsistent with other guidelines. As most
children with type 1 diabetes and positive tTG-Ab are asymptomatic, a biopsy is
still frequently required to confirm the diagnosis.
In asymptomatic patients, the indication for a gluten-free diet or further
follow-up should be carried out in cooperation with the paediatric
gastroenterologist.
Other forms of diabetes in childhood and adolescence
Other forms of diabetes in childhood and adolescence
Type 2 diabetes
Type 2 diabetes in adolescents should be diagnosed according to the limits for
fasting glucose and oral glucose tolerance test (OGTT) using the standard or
reference method.
If the following limit values are exceeded, the result in asymptomatic patients
must be confirmed by a second test on a different day:
-
Fasting glucose:>126 mg/dl (>7.0 mmol/l) and
-
OGTT: 2 h value>200 mg/dl (>11.1 mmol/l) [Genuth et al. 2003].
Additional laboratory tests can provide information on the
differentiation between type 2 diabetes and type 1 diabetes:
-
C-peptide and
-
Diabetes-specific autoantibodies (GAD, IA-2, ICA, IAA, ZnT8) [Alberti et
al. 2004; Genuth et al. 2003].
In the treatment of type 2 diabetes in adolescents ([Fig. 2]) [Alberti et al. 2004]), the target fasting glucose should
be<126 mg/dl and the target HbA1c value should be<7% [Zeitler et al. 2014;
UK Prospective Diabetes Study (UKPDS) Group 1998; Holman et al. 2008].
Fig. 2 Diagram for treating type 2 diabetes in children and adolescents Source: Diagnosis,
Therapy and Follow-Up of Diabetes Mellitus in Children
and Adolescents. S3-Guideline of the DDG and AGPD 2015. German Association of the
Scientific Medical Professional Societies/AWMF registration
number 057–016 [rerif].
Training for adolescents with type 2 diabetes should include nutritional
counselling and guidance on physical activity as part of a structured obesity
programme [Reinehr et al. 2007; Working Group for Obesity in Childhood and
Adolescence/Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA)
2008].
In addition, individually tailored modular training for type 2 diabetes should
take place using the relevant contents from the type 1 diabetes training.
At a starting HbA1c value of≥9% or spontaneous hyperglycaemia≥250 mg/dl and with
signs of absolute insulin deficiency (ketonuria, ketoacidosis), an initial
insulin therapy should be started. In all other cases, metformin is the first
drug of choice for drug therapy in children and adolescents [Shimazaki et al.
2007; UK Prospective Diabetes Study (UKPDS) Group 1998; Jones et al. 2002;
Gottschalk et al. 2007; Zeitler et al. 2014]. As of recently, long-acting
incretin mimetics can also be used in childhood and adolescence in addition to
metformin [7].
Monogenetic diabetes
A molecular genetic diagnosis of the most common MODY forms can be recommended in
cases of justified assumptions because of its importance for therapy, long-term
prognosis and genetic counselling of families [Hattersley et al. 2006; Ellard et
al. 2008] ([Table 3]).
Table 3 The most common MODY forms and their clinical
characteristics.
|
MODY type (international share in percent); heredity
|
Age (Y) at manifestation
|
Severity of hyperglycaemia
|
Clinical picture
|
|
HNF1A-MODY (MODY3) HNF-1α-(20–50%) autosomal dominant
|
14 (4–18)
|
Severe hyperglycaemia
|
-
Strong increase of BG in OGTT (>90 mg/dl), low
renal threshold (frequent glucosuria in BG
values)<180 mg/dl (<10 mmol/l))
-
Increasing hyperglycaemia with age
-
Response to sulfonylureas/glinides
|
|
GCK-MODY (MODY2) Glucokinase (20–50%) autosomal dominant
|
10 (0–18)
|
Mild hyperglycaemia
|
-
Often by chance
-
Fasting BG slightly increased between 99 and 144
mg/dl (5.5–8 mmol/l)
-
BG increase in the OGTT low (by<63 mg/dl or<3.5
mmol/l)
-
No BG deterioration in old age
-
Rarely microvascular or macrovascular complications,
even without drug therapy
|
|
HNF4A-MODY (MODY1) HNF-4α-(1–5%) autosomal dominant
|
17 (5–18)
|
Significantly hyperglycaemic
|
|
MODY: Maturity onset diabetes of the young; HNF-1α: hepatic nuclear
factor 1 alpha; BG: blood glucose; OGTT: oral glucose tolerance test;
HNF-4α: hepatic nuclear factor 4 alpha.
Before the affected genes are sequenced, counselling and information must be
provided in accordance with the Gene Diagnostics Act, especially on the right to
knowledge and ignorance of genetic information [Murphy et al. 2008; McDonald and
Ellard 2013; Ellard et al. 2008; Badenhoop et al. 2008; Gene Diagnostics Act
2009].
Neonatal diabetes mellitus (NDM)
A special form of genetic diabetes is neo-natal diabetes mellitus (NDM) and
diabetes that manifests within the first 6 months of life. Clinically, they are
classified into 2 subgroups: transient (TNDM) and permanent (PNDM) neonatal
diabetes mellitus. For diagnosis of neonatal diabetes or diabetes manifestation
up to and including the sixth month of life, see the box “Neonatal diabetes –
diagnostic procedure”.
In the case of etiologically unexplained neonatal diabetes mellitus and diabetes
mellitus, which manifests itself up to the 6th month of life, a molecular
genetic analysis should be performed as early as possible in order to start
appropriate therapy for sulfonylurea-sensitive mutations as early as possible
[Flanagan et al. 2006; Babenko et al. 2006; Klupa et al. 2008; Battaglia et al.
2012; Shah et al. 2012].
In most cases, insulin therapy is administered first if neonatal diabetes is
present. Under in-patient conditions and tight controls, an initial therapy
attempt with sulfonylureas may be useful if the result of the molecular genetic
examination is expected shortly. In the presence of a mutation of the KCNJ11 or
the ABCC8 gene, therapy with sulfonylureas should be attempted as early as
possible [Hattersley et al. 2006; Pearson et al. 2006; Mlynarski et al. 2007;
Koster et al. 2008; Slingerland et al. 2008; Thurber et al.].
Diabetes in cystic fibrosis
Since diabetes in cystic fibrosis is often clinically difficult to detect,
children with cystic fibrosis as of age 10 should receive an oral glucose
tolerance test annually [Lanng et al. 1994]. New studies show better results
using CGM to detect glucose variability [Chan 2018].
With a confirmed diagnosis of diabetes, early treatment of cystic
fibrosis-related diabetes (CFRD) should be initiated [Nousia-Arvanitakis et al.
2001; Rolon et al. 2001; Lanng et al. 1994; Dobson et al. 2002; Frost et al.,
2018].
Insulin is to be used for long-term therapy of CF-related diabetes, however
within the first 12 months after diagnosis, a therapy attempt with glinides or
sulphonylureas may be undertaken [Ballmann et al. 2014; O’Riordan et al.
2008].
If cystic fibrosis is present, a high-calorie, high-fat diet should also be
followed after the diagnosis of diabetes. Calorie reduction is contraindicated
[O’Riordan et al. 2008].
Imprint (German)
The evidence-based guideline was prepared on behalf of the German Diabetes Society
(Deutsche Diabetes Gesellschaft – DDG). The German Diabetes Society is represented
by its president (2019–2021 Dr. Monika Kellerer) and the DDG guideline officer
(Prof. Dr. Andreas Neu).
The Guidelines Group is composed of members of the Association for Paediatric
Diabetology (AGPD), members of the 2009 Guidelines Group and a patient
representative.
Expert group responsible for the 2015 version of the guidelines:
Prof. Dr. A. Neu, Tübingen (Coordinator)
J. Bürger-Büsing, Kaiserslautern (patient representative)
Prof. Dr. T. Danne, Hannover
Dr. A. Dost, Jena
Dr. M. Holder, Stuttgart
Prof. Dr. R. W. Holl, Ulm
Prof. Dr. P.-M. Holterhus, Kiel
PD Dr. T. Kapellen, Leipzig
Prof. Dr. B. Karges, Aachen
Prof. Dr. O. Kordonouri, Hannover
Prof. Dr. K. Lange, Hannover
S. Müller, Ennepetal
PD Dr. K. Raile, Berlin
Dr. R. Schweizer, Tübingen
Dr. S. von Sengbusch, Lübeck
Dr. R. Stachow, Westerland
Dr. V. Wagner, Rostock
PD Dr. S.Wiegand, Berlin
Dr. R. Ziegler,Münster
Literature research:
Dr. Barbara Buchberger (MPH), Hendrick Huppertz, Beate Kossmann, Laura Krabbe, Dr.
Jessica Tajana Mattivi at the Endowed Chair of Medical Management/Stiftungslehrstuhl
für Medizinmanagement at the University of Duisburg-Essen (Head Prof. Dr. Jürgen
Wasem)
Methodical support:
Dr. Monika Nothacker, Berlin, German Association of the Scientific Medical
Professional Societies/Arbeitsgemeinschaft der wissenschaftlichen medizinischen
Fachgesellschaften (AWMF)
Editorial work:
Andrea Haring, Berlin
Cornelia Berg, Tübingen
External reviewer:
Prof. Dr. H. Krude
Specialist in paediatrics, additional training in paediatric endocrinology and
diabetology, for the Paediatric Endocrinology Working Group (APE), Berlin (Diabetes
and Thyroid Diseases)
Prof. Dr. K. P. Zimmer
Specialist in paediatrics and adolescent medicine, additional training in paediatric
gastroenterology, Giessen (Diabetes and Celiac Disease)
Prof. Dr. M. Ballmann
Specialist in paediatrics and adolescent medicine, additional specialisation in
paediatric pneumology, for the Paediatric Pneumology Working Group, Siegen (Diabetes
in Cystic Fibrosis)
Prof. Dr. A. Fritsche
Specialist in internal medicine, diabetologist, Tübingen
Coordination of the review 2013–2015:
Prof. Dr. A. Neu, Tübingen
German Diabetes Association: Clinical Practice Guidelines This is a translation
of the DDG clinical practice guidelinepublished in Diabetol Stoffwechs 2023; 18
(Suppl 2): S148–S161DOI 10.1055/a-2076-0009
